Cargando…

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a manner similar to FVIIIa. However, details of the emicizumab–antigen interactions have not been reported so far. In this study, we first showe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitazawa, Takehisa, Esaki, Keiko, Tachibana, Tatsuhiko, Ishii, Shinya, Soeda, Tetsuhiro, Muto, Atsushi, Kawabe, Yoshiki, Igawa, Tomoyuki, Tsunoda, Hiroyuki, Nogami, Keiji, Shima, Midori, Hattori, Kunihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Schattauer GmbH 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292136/ https://www.ncbi.nlm.nih.gov/pubmed/28451690 http://dx.doi.org/10.1160/TH17-01-0030

Ejemplares similares

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro
por: Noguchi-Sasaki, Mariko, et al.
Publicado: (2018)

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity
por: Sampei, Zenjiro, et al.
Publicado: (2014)

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
por: Sampei, Zenjiro, et al.
Publicado: (2013)

SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa
por: Childers, Kenneth C., et al.
Publicado: (2022)

A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa
por: Kundu, Sibsankar, et al.
Publicado: (2021)

Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa
por: Yoon, Hyun Jung, et al.
Publicado: (2023)

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays
por: Adamkewicz, Joanne I., et al.
Publicado: (2019)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults
por: Persson, Paula, et al.
Publicado: (2023)

Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab
por: Mak, Stefanie, et al.
Publicado: (2022)

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

The Interaction of Factor Xa and IXa with Non-Activated Antithrombin in Michaelis Complex: Insights from Enhanced-Sampling Molecular Dynamics Simulations
por: Balogh, Gábor, et al.
Publicado: (2023)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential
por: Nakajima, Yuto, et al.
Publicado: (2022)

Lifetime imaging of GFP at CoxVIIIa reports respiratory supercomplex assembly in live cells
por: Rieger, Bettina, et al.
Publicado: (2017)

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Regulation of collective cell migration by RhoGAP myosin IXA
por: Omelchenko, Tatiana
Publicado: (2012)

Emicizumab-induced photosensitivity
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target
por: Ankrom, Wendy, et al.
Publicado: (2016)

Myosin IXa Binds AMPAR and Regulates Synaptic Structure, LTP, and Cognitive Function
por: Folci, Alessandra, et al.
Publicado: (2016)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

The dosing conundrum of emicizumab: To waste product or not?
por: Young, Guy
Publicado: (2023)

A new variant in PHKA2 is associated with glycogen storage disease type IXa
por: Rodríguez-Jiménez, Carmen, et al.
Publicado: (2017)

Functional assembly of intrinsic coagulation proteases on monocytes and platelets. Comparison between cofactor activities induced by thrombin and factor Xa
Publicado: (1992)

Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
por: Yagyuu, Takahiro, et al.
Publicado: (2022)

Efficient production of bispecific antibody by FAST-Ig(TM) and its application to NXT007 for the treatment of hemophilia A
por: Koga, Hikaru, et al.
Publicado: (2023)

Antibacterial potential of a basic phospholipase A(2) (VRV-PL-VIIIa) from Daboia russelii pulchella (Russell’s viper) venom
por: Sudharshan, Shivalingaiah, et al.
Publicado: (2015)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO
por: Reed, Christopher R., et al.
Publicado: (2021)

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage
por: Yamada, Yuya, et al.
Publicado: (2022)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
por: Shima, Midori, et al.
Publicado: (2019)

Modification of tobacco plant development by sense and antisense expression of the tomato viroid-induced AGC VIIIa protein kinase PKV suggests involvement in gibberellin signaling
por: Hammond, Rosemarie W, et al.
Publicado: (2009)

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
por: Sampei, Zenjiro, et al.
Publicado: (2018)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tqv8g74g3ceonbi1hori39dseb